Celebrating its 21st birthday, EmCell offers 15% discount to all patients coming between January 15 – February 15, 2015.
*This offer is not added with other discounts
People with macular degeneration had their eyesight improved after the stem cell transplantation as research by scientists from Massachusetts company Advanced Cell Technology shows.
Researchers from the Institute for Research in Immunology and Cancer at the Université de Montréal have discovered a new molecule, the first of its kind, that helps multiply stem cells in a transplant of cord blood. T
The first ever study of treating multiple sclerosis with stem cells derived from placenta showed no safety issues and stability or improvement in the patients' condition.All news
Following successful animal trials started in the 1970’s by a group of young scientists at the National Medical University, in 1985, EmCell founders started working with fetal stem cells and later applying them in clinical practice. They were prompted by the experimental work with animals that had proved positive impact of stem cells harvested from animal fetuses on neurodystrophy in denervated organs and tissues. In 1987, stem cells were applied by EmCell founders, for the first time, for treatment of cytostatic myelodepression and aplastic anemia in the National Medical University of Ukraine.
In 1991, after obtaining the permission of the Ukrainian Health Ministry, fetal stem cells started to be widely used for different diseases and conditions such as dystrophy, diseases causing cell deficit, sclerosis and malignant processes. A group of doctors developed and introduced a reliable and safe method of fetal stem cell treatment that proved effective for certain diseases and conditions and showed good results in different patients. At the same time, no side effects or complications were reported, which allowed for extension of the range of diseases in which stem cell therapy could be applied.
We were the first in the world to develop our own stem cell treatment protocols for such diseases as multiple sclerosis, diabetes, and autism.
In 1994, our extensive clinical experience led to the launching of the world’s first specialized cell therapy center, EmCell, that used fetal stem cells for therapeutic purposes, in Kyiv, Ukraine.
Over the years, we have performed more than 8,500 fetal stem cell transplantations to patients from 90 countries around the world. Our treatment has helped to save and prolong patients’ lives, restore their tissue and organ functions, and achieve positive results in treating diseases in which routine methods have proved ineffective.
All fetal stem cell treatment methods used at EmCell are patent-protected in different countries. EmCell currently holds 19 patents in the US, the Netherlands, Greece, Russia, and Ukraine. EmCell was the first in the world to obtain patents for clinical application of fetal stem cell suspensions: our first patent application dates back to October 18, 1993. Our patents cover methods of hematopoietic stem cell harvesting, creation of cell suspensions, treatment of autism, multiple sclerosis, diabetes mellitus, aplastic anemia, psoriasis, cancer etc.
Since 1991, 7 MMS theses were written on application of fetal stem cells in different diseases and conditions including diabetes, intestinal diseases, cancer, rheumatoid arthritis etc.
Starting from 1994, we operated under a general license for medical practice. In 2011, a new regulation required all clinics working with stem cells to apply for a special license, the only one allowing legal manipulations with stem cells. EmCell was also the first in Ukraine to receive the state license for fetal cell bank operation.
BBC documentary called EmCell the "Last Hope Clinic" because we treated and followed-up the most complicated clinical cases from all over the world.
During the years of intensive work, EmCell team won international acclaim in the field of research and clinical application of fetal stem cells. EmCell professionals authored more than 300 scientific works published in the national as well as international magazines and congress proceedings.
Today, EmCell consists of a Clinical Department and a laboratory complex operating in its own 1,200 sq m renovated building with 8 VIP rooms offering patients comfort and hospitality.
The Clinical Department employs highly qualified, experienced doctors with different specializations who also hold scientific degrees and have numerous patents to their names. Our professional team of nurses and assistants completes our clinical department staff.
The Clinical Department offers both diagnostic (ultrasound, ECG, EchoCG, Doppler, spirography etc.) and consultative services.
The Laboratory Complex consists of five EmCell lab units functioning as a single department:
Biotechnological stages of work with fetal cell suspensions include:
Creation of cell suspensions and their transplantation at the same facility is a perfect combination as it guarantees the high quality of the cell transplants and allows achieving the best effects.
We care about our patients and our reputation worldwide. We keep up to date with modern technology and innovations and advance our methods of work in order to ensure the highest quality and safety standards of the cells. Our specialists in all fields continuously work on the advancement of stem cell suspension preparation and proper application technologies, they prepare new patents and write experience-based articles on different aspects of stem cell application, learn and introduce new methods and approaches. All of this is for the patient’s benefit. The best award for EmCell is successful treatment and improvements in our patients, their words of gratitude and smiles on their faces.